Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-11-12 / Cancers (Basel) 2018 Nov;10(11)Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
/in Dendritic Cells, International Publications, NSCLC /von 2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
/in Dendritic Cells, International Publications /von 2018-10-22 / Cytotherapy 2018 Nov;20(11):1309-1323Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-5129Phase I/II clinical trial of a Wilms‘ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
/in Dendritic Cells, International Publications /von 2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-130Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-10-01 / Front Immunol 2018;9:2265Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de